Beyond COVID-19: Life sciences reimagined
The COVID-19 pandemic has transformed entire industries in just a few short months, and life sciences is certainly no exception. From payer-mix changes to pricing and profitability concerns, the industry is fraught with market and other pressures. In particular, biopharma companies have faced significant challenges due to constrained access to key customers and largely grounded sales teams. However, these circumstances have also presented new opportunities for these organizations, including accelerated adoption of digital tools and approaches.
Insights from this white paper include:
- Commercial operations
- HCP needs and relationships
- Marketing and the sales model
- Patient engagement
- Medical affairs and R&D
- The post-pandemic outlook for pharma
COVID-19: Accelerating digital transformation in life sciences white paper includes insights from AstraZeneca, Merck, Sandoz, EY, ViiV Healthcare, Janssen and Otsuka North America Pharmaceutical Business.
Please subscribe to view the analysis report